Home / Current Issue / Paper 1706023
Novel Approaches to Depression Treatment: Integrating Pharmacological and Non-Pharmacological Strategies
Subject area: Science,Engineering and Technology · Area of research: Pharmacology(pharmacy)
Abstract
Major depressive illness (MDD) is a persistent and incapacitating Psychological disorder affecting more than 280 million people worldwide. Depression is approximately 50% more frequent compared to men in women. Approximately 10% of women worldwide suffer from antenatal and postnatal depression. More than 700,000 people commit suicide annually. When it comes to causes of death, suicide ranks fourth among those between the ages of 15 and 29. Depression is characterized as an ongoing feeling of melancholy, despair, and a loss of interest in life, which affects one's thoughts, emotions, and general well-being. Antidepressants based on monoamines were initially developed for severe depression. However, due to delayed therapeutic effectiveness and one-third of patients showing partial response to single-drug therapy, alternative methods must be explored. Recent advancements include complementary medications and nonpharmacological treatments. This overview traces the historical development of antidepressants from their inception to modern advancements. Today's pharmacological techniques include targeting receptors like ketamine and GABA and addressing biological processes such as the HPA axis and gut microbiota. Novel non-pharmacological approaches like psilocybin therapy, CBT, ECT, TMS, and lifestyle interventions offer diverse treatment options for depression.
Keywords
Antidepressant , Major Depressive Disorder, Non-Pharmacological Therapy, Pharmaceutical technique
How to cite this paper
@article{1706023,
author = {Sakshi Gupta, Dr. Manish Kumar Shakya},
title = {Novel Approaches to Depression Treatment: Integrating Pharmacological and Non-Pharmacological Strategies},
journal = {Iconic Research And Engineering Journals},
year = {2024},
volume = {8},
number = {1},
pages = {100-112},
issn = {2456-8880},
url = {https://www.irejournals.com/formatedpaper/1706023.pdf},
abstract = {Major depressive illness (MDD) is a persistent and incapacitating Psychological disorder affecting more than 280 million people worldwide. Depression is approximately 50% more frequent compared to men in women. Approximately 10% of women worldwide suffer from antenatal and postnatal depression. More than 700,000 people commit suicide annually. When it comes to causes of death, suicide ranks fourth among those between the ages of 15 and 29. Depression is characterized as an ongoing feeling of melancholy, despair, and a loss of interest in life, which affects one's thoughts, emotions, and general well-being. Antidepressants based on monoamines were initially developed for severe depression. However, due to delayed therapeutic effectiveness and one-third of patients showing partial response to single-drug therapy, alternative methods must be explored. Recent advancements include complementary medications and nonpharmacological treatments. This overview traces the historical development of antidepressants from their inception to modern advancements. Today's pharmacological techniques include targeting receptors like ketamine and GABA and addressing biological processes such as the HPA axis and gut microbiota. Novel non-pharmacological approaches like psilocybin therapy, CBT, ECT, TMS, and lifestyle interventions offer diverse treatment options for depression.},
keywords = {Antidepressant , Major Depressive Disorder, Non-Pharmacological Therapy, Pharmaceutical technique},
month = {July},
}